BACKGROUND: We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx). METHODS:Patients (n = 118) at risk of CMV infection were randomized 1:2 to either 5 months or variable length valganciclovir prophylaxis (5-11 mo post-LTx), as determined by the QuantiFERON (QFN)-CMV assay. Patients with a negative QFN-CMV assay (< 0.2 IU/mL) received prolonged valganciclovir prophylaxis. RESULTS: The primary endpoint that was the incidence of CMV infection in the lung allograft within 18 months of LTx was significantly reduced in the QFN-CMV directed arm (37% versus 58%, P = 0.03). Secondary endpoints that included blood viremia, acute rejection, and chronic lung allograft dysfunction did not differ between the 2 arms. Of the 80/118 patients who ceased antiviral prophylaxis at 5 months, the incidence of viremia (> 600 copies/mL) within the blood was significantly reduced in patients with a positive QFN-CMV assay compared with those without protective immunity (13% versus 67%, P = 0.0003), as was the incidence of severe viremia (> 10 000 copies/mL) (3% versus 50%, P < 0.001). Ceasing antiviral prophylaxis at 11 months in patients with a negative assay was associated with a 25% incidence of late CMV viremia. CONCLUSIONS: Cytomegalovirus immune monitoring allows an individualized approach to CMV prophylaxis and reduces late CMV infection within the lung allograft.
RCT Entities:
BACKGROUND: We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx). METHODS:Patients (n = 118) at risk of CMV infection were randomized 1:2 to either 5 months or variable length valganciclovir prophylaxis (5-11 mo post-LTx), as determined by the QuantiFERON (QFN)-CMV assay. Patients with a negative QFN-CMV assay (< 0.2 IU/mL) received prolonged valganciclovir prophylaxis. RESULTS: The primary endpoint that was the incidence of CMV infection in the lung allograft within 18 months of LTx was significantly reduced in the QFN-CMV directed arm (37% versus 58%, P = 0.03). Secondary endpoints that included blood viremia, acute rejection, and chronic lung allograft dysfunction did not differ between the 2 arms. Of the 80/118 patients who ceased antiviral prophylaxis at 5 months, the incidence of viremia (> 600 copies/mL) within the blood was significantly reduced in patients with a positive QFN-CMV assay compared with those without protective immunity (13% versus 67%, P = 0.0003), as was the incidence of severe viremia (> 10 000 copies/mL) (3% versus 50%, P < 0.001). Ceasing antiviral prophylaxis at 11 months in patients with a negative assay was associated with a 25% incidence of late CMV viremia. CONCLUSIONS: Cytomegalovirus immune monitoring allows an individualized approach to CMV prophylaxis and reduces late CMV infection within the lung allograft.
Authors: Aurora Paez-Vega; Sara Cantisan; José Manuel Vaquero; Elisa Vidal; Antonio Luque-Pineda; María Ángeles Lobo-Acosta; Ana Belén Pérez; Rodrigo Alonso-Moralejo; David Iturbe; Victor Monforte; Isabel Otero-Gonzalez; Amparo Pastor; Piedad Ussetti; Julian Torre-Cisneros Journal: BMJ Open Date: 2019-08-15 Impact factor: 2.692
Authors: Ambreen Azhar; Makoto Tsujita; Manish Talwar; Vasanthi Balaraman; Anshul Bhalla; James D Eason; Simonne S Nouer; Keiichi Sumida; Adam Remport; Isaac E Hall; Randi Griffin; George Rofaiel; Miklos Z Molnar Journal: Ren Fail Date: 2022-12 Impact factor: 3.222
Authors: Omid Rezahosseini; Dina Leth Møller; Andreas Dehlbæk Knudsen; Søren Schwartz Sørensen; Michael Perch; Finn Gustafsson; Allan Rasmussen; Sisse Rye Ostrowski; Susanne Dam Nielsen Journal: Front Immunol Date: 2020-10-15 Impact factor: 7.561